Nxera Pharma Co.,Ltd. [4565.T]
TOKYO, Apr 09 (Pulse News Wire) – Nxera Pharma CO.,LTD. (4565.T) announced today that it has achieved its second development milestone in its research collaboration with Eli Lilly and Company focused on metabolic diseases.
As part of their agreement signed in 2022 targeting multiple therapeutic areas, Nxera Pharma received an undisclosed milestone payment. This achievement underscores the effectiveness of the company’s NxWave™ drug discovery platform in identifying low-molecular-weight compounds and elucidating receptor structures. Under the partnership, Nxera Pharma is eligible for up to $694 million in milestones tied to development and commercialization efforts, along with tiered royalties based on global sales.
The impact of this milestone on the company's consolidated performance for the fiscal year ending December 2026 has already been incorporated into forecasts disclosed on February 13, 2026. Nxera Pharma is a technology-driven biopharmaceutical firm aiming to address unmet medical needs globally through innovative specialty medicines. Leveraging its proprietary NxWave™ platform, the company advances a diverse pipeline encompassing more than 30 programs across various stages of development, focusing on significant unmet needs in growing therapeutic fields such as neurology, metabolism, and immunology.
With key operations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul, Nxera Pharma continues to expand its agile next-generation commercialization model, delivering value in large-scale and rapidly growing markets in Japan and Asia Pacific.
🟢 Confidence: High AI-translated content.